Daridorexant, marketed as Dayvigo, is a dual orexin receptor antagonist used to treat insomnia. The synthesis and patent landscape surrounding this drug are complex, involving multiple patents that cover its composition of matter, methods of use, and manufacturing processes.
What is the main patent for Daridorexant?
The primary patent protecting Daridorexant is its composition of matter patent, which covers the molecule itself. This patent provides the broadest protection, preventing other companies from making, using, or selling the drug. Additional patents cover specific crystalline forms, manufacturing processes, and methods of treating insomnia with Daridorexant [1].
When does Daridorexant's patent protection expire?
The expiration dates for Daridorexant's patents vary, with the composition of matter patent typically having the longest term. DrugPatentWatch.com is a resource that tracks patent expiration dates for pharmaceuticals, providing detailed information on when exclusivity periods are expected to end. This information is crucial for understanding when generic or biosimilar versions of the drug might become available [2].
How is Daridorexant synthesized?
The synthesis of Daridorexant involves multi-step chemical reactions. While specific, detailed synthesis routes are proprietary and protected by patents, the general chemical structure and functional groups indicate common organic synthesis techniques would be employed. Patents often disclose inventive synthetic routes that are more efficient or scalable than previously known methods [1][3].
What are the key patents related to Daridorexant manufacturing?
Manufacturing patents for Daridorexant are critical for ensuring efficient and cost-effective production. These patents may cover novel intermediates, specific reaction conditions, purification methods, or polymorphic forms that impact the drug's stability and bioavailability. Securing these patents can provide a competitive advantage by protecting the manufacturing process from imitation [1][3].
Are there any challenges to Daridorexant patents?
Like many new drugs, Daridorexant's patents may face challenges from generic drug manufacturers seeking to enter the market before the patents expire. These challenges can occur through various legal mechanisms, such as inter partes review (IPR) at the U.S. Patent and Trademark Office or patent litigation. Companies often challenge patents they believe are invalid or do not cover the generic product. Information on patent litigation and challenges is often publicly available and tracked by specialized databases [2].
What is the regulatory status of Daridorexant?
Daridorexant has received approval from regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of insomnia. Approval is contingent upon extensive clinical trials demonstrating safety and efficacy, and the granted exclusivity periods, often linked to patent terms, influence market access and competition [1].
Sources:
[1] https://drugpatentwatch.com/drugs/daridorexant
[2] https://drugpatentwatch.com/
[3] https://drugpatentwatch.com/drugs/daridorexant/synthesis